XLV - Health Care Select Sector SPDR ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
83.12
-0.16 (-0.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close83.28
Open83.45
Bid0.00 x 2200
Ask0.00 x 3000
Day's Range82.99 - 83.55
52 Week Range75.34 - 91.79
Volume5,770,209
Avg. Volume8,202,235
Net Assets15.28B
NAV82.22
PE Ratio (TTM)N/A
Yield1.51%
YTD Return-0.16%
Beta (3y)0.96
Expense Ratio (net)0.14%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • Why health care will cost you more next year
    Yahoo Finance Video18 hours ago

    Why health care will cost you more next year

    Obamacare costs are expected to rise as healthier people forgo coverage. Yahoo Finance's Seana Smith, Rick Newman and Dion Rabouin discuss.

  • MARKETS: Most investors don't expect recession in 2018
    Yahoo Finance Video8 days ago

    MARKETS: Most investors don't expect recession in 2018

    Yahoo Finance's Seana Smith speaks with Meridian Equity Partners' Jonathan Corpina about the possibility of a recession this year.

  • Health care stocks soar, did Trump just give them the all...
    CNBC Videos12 days ago

    Health care stocks soar, did Trump just give them the all...

    After Trump's announcement, are health care stocks in the clear? With CNBC's Eamon Javers, CNBC's Melissa Lee, and the Fast Money traders, Tim Seymour, David Seaburg, Brian Kelly and Steve Grasso.

  • Yahoo Finance Live: The Final Round - May 11th, 2018
    Yahoo Finance Video12 days ago

    Yahoo Finance Live: The Final Round - May 11th, 2018

    Yahoo Finance's LIVE stock market coverage and analysis.

  • Investopedia5 days ago

    Why J&J's Stock May Plunge 10%

    Johnson & Johnson ( JNJ) shares may drop by about 10% based on an analysis of the technical chart. Should shares of the stock fall an additional 10%, it would mean Johnson and Johnson would have dropped by nearly 25% from its intraday high of around $148 on January 22. The technical setup continues to be negative in the stock, and it appears shares could fall from roughly $124.25 to about $111.33, a drop of 10.4%.

  • MarketWatch9 days ago

    President Trump’s big drug price speech boosts pharma stocks

    After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.

  • ETF Trends12 days ago

    6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

    Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to "global freeloading" that has allowed foreign countries to pay less on American-manufactured medicines. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, gained 1.5% Friday while the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, rose 2.7% and VanEck Vectors Generic Drugs ETF (GNRX) , which focuses on generic drug producers, added 2.2%.

  • Trump lets drug companies off the hook
    Yahoo Finance12 days ago

    Trump lets drug companies off the hook

    After several delays, President Trump unveiled a plan to lower drug prices. Don't bank on it just yet.

  • MarketWatch12 days ago

    Drug stocks slip, then swing back even higher after Trump unveils drug cost cutting plan

    Healthcare stocks dipped after President Donald Trump started presenting his plan to cut prescription drug costs, then bounced sharply to trade even higher than pre-speech levels. The SPDR Health Care Select Sector ETF was up about 0.5% before Trump's speech began, then slid to be down 0.1% swinging higher to be up 1.1% at a new intraday high. Some changes to policy announced by Trump and Health and Human Services Secretary Alex Azar included drug price negotiation by government programs, an end to the "gag rule" on pharmacists--who cannot disclose if drug products can be bought for cheaper without using a health plan -- and disclosure of drugs' list prices pharmaceutical advertisements.

  • Benzinga12 days ago

    Trump Strikes At PBMs, Insurers, Drugmakers With Plans To Lower Consumer Prices

    Stocks representing the U.S. drug supply chain temporarily tumbled Friday as President Donald Trump proposed a broad plan to lower consumer health costs. Last year, it increased federal lobbying spending by 30 percent, and it may maintain such investments to prevent future follow-through.

  • What Were the Hiring and Firing Trends in March?
    Market Realist13 days ago

    What Were the Hiring and Firing Trends in March?

    The “Job Openings and Labor Turnover Survey” (or JOLTS) data for March was reported on May 8 and contains key information about job openings and total separations. The total number of separations include layoffs, retirements, and voluntary quits. As per the latest JOLTS report, the total separations for March came in at 5.3 million at a rate of 3.6% of the total workforce, an increase from the February reading of 5.2 million and 3.5%, respectively.

  • FDA Approves JNJ’s Darzalex in Combination with VMP
    Market Realist15 days ago

    FDA Approves JNJ’s Darzalex in Combination with VMP

    Johnson & Johnson’s (JNJ) Darzalex injection is a CD-38 surface protein–directed antibody approved for the treatment of multiple myeloma. Today, JNJ announced that the US Food & Drug Administration (or FDA) approved Darzalex in combination with other drugs for the treatment of multiple myeloma, marking the fifth indication for which Darzalex has FDA approval.

  • Analyzing Merck’s Revenue in 1Q18
    Market Realist15 days ago

    Analyzing Merck’s Revenue in 1Q18

    Merck (MRK), one of the largest pharmaceutical companies worldwide, is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company reported its 1Q18 results on May 1. During the quarter, Merck surpassed analysts’ EPS (earnings per share) estimate of $1, but missed their revenue estimate of $10.1 billion, reporting EPS of $1.05 on revenue of $10.0 billion.

  • Which Sector Posted Major Job Gains in April?
    Market Realist20 days ago

    Which Sector Posted Major Job Gains in April?

    The ADP March employment report was published on May 2. The report offered deeper insight into employment trends across different sectors in the US employment market. ADP and Moody’s Analytics prepared the monthly report.